Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Authors' conclusion
In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF. There is a need for further studies on the cardioprotective role of lobeglitazone, a novel thiazolidinedione.
Study context
- Population
- Patients with T2D admitted for acute ischemic stroke in 2014–2018, nationwide health claims data in Koreacohort of 70,897
- Participants
- 20,869 vs 62,607
- Comparison
- Lobeglitazone or pioglitazone treatment vs no treatment
- Casesn = 20,869
- Controlsn = 62,607reference
- Outcome
- Composite of:
- Recurrent stroke
- MI
- All-cause death
- Follow-up
- Before December 2020
Methodological detailsnationwide, population-based health claims data, incidence density sampling, exact matching on sex, age, comorbidities and medications, multivariable conditional logistic regression
- Nationwide
- Population-based health claims data
- Incidence density sampling
- Exact matching on sex, age, comorbidities and medications
- Multivariable conditional logistic regression
Main finding
As reported in the abstract
Adjusted odds ratio (95% CI)P value
Lobeglitazone
0.74(0.61–0.90)
P = 0.002Pioglitazone
0.71(0.64–0.78)
P < 0.001Observational data: associations, not effects.
Safety
Heart failure (HF)
| aOR (95% CI) | P value | ||
|---|---|---|---|
| LobeglitazoneDid not increase risk of HF | 0.90 (0.66–1.22) | P = 0.492 | |
| 0.512Adjusted odds ratio (log scale) |
Original publication
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. Cardiovasc Diabetol. Published 5 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →